The ARIA® oncology information system (OIS) version 15.5 was recently named a Category Leader in the 2018 Best in KLAS: Software and Services Report by KLAS, an independent research firm specializing in monitoring and reporting on the performance of healthcare vendors.
MUNICH, April 3, 2018 – Today Brainlab announced an agreement with Varian to address interoperability of Brainlab ExacTrac® versions 5.x, 6.x and new product generations currently under development, with Varian’s Clinac® platform, TrueBeam™ and Edge® systems. To support and enhance the interoperability between the companies’ products, Brainlab and Varian will complete joint testing, verification and validation.
PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced the Bravos™ afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic experience by simplifying brachytherapy treatment and providing greater workflow efficiency. Bravos integrates with Varian's BrachyVision™ for treatment planning and offers interoperability with Varian ARIA® oncology information system. Bravos has received CE mark and FDA 510(k) clearance.
The Halcyon™ system is Varian’s newest cancer treatment device, engineered to simplify and enhance virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT). Halcyon combines fast volumetric imaging and dose delivery with the power of Eclipse™ treatment planning system in a transformative platform.
TrueBeam system brings leading edge cancer care to communities by positioning clinics at the forefront in the fight against cancer. Designed from the ground up to treat moving targets with advanced speed and accuracy, the TrueBeam platform is a fully-integrated system for image-guided radiotherapy and radiosurgery.
Novalis Radiosurgery strengthens the strategic position of facilities dedicated to a comprehensive and focused vision for excellence in targeted cancer treatments.